| Literature DB >> 21441027 |
Bernard Barlaam1, Richard Ducray, Christine Lambert-van der Brempt, Patrick Plé, Catherine Bardelle, Nigel Brooks, Tanya Coleman, Darren Cross, Jason G Kettle, Jon Read.
Abstract
Optimization of our bis-anilino-pyrimidine series of EphB4 kinase inhibitors led to the discovery of compound 12 which incorporates a key m-hydroxymethylene group on the C4 aniline. 12 displays a good kinase selectivity profile, good physical properties and pharmacokinetic parameters, suggesting it is a suitable candidate to investigate the therapeutic potential of EphB4 kinase inhibitors.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21441027 DOI: 10.1016/j.bmcl.2011.03.009
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823